Returns | 1W : -0.2% , 1M : -5.7%,1Y : 66.1% |
LT :   |
    Long Term Analysis
Fundamentals : Average
Valuation : Bad [Stock is Expensive] Debt : High |
ST :   |
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Downward Pledged Shares : None or < 25% |
Peers & Returns | 1W | 1M | 1Y |
BAJAJ HEALTHCARE | -0.2% | -5.7% | 66.1% |
SUN PHARMACEUTICAL INDUSTRIES | 2.8% | 10.2% | 40.1% |
DR REDDYS LABORATORIES | 7.8% | 18.3% | 26.4% |
DIVIS LABORATORIES | 1.7% | 12% | 63.2% |
CIPLA | 7.2% | 22.8% | 58.3% |
BIOCON | -1.4% | 3.4% | 14.3% |
AUROBINDO PHARMA | 8.5% | 17.7% | 77.9% |
LUPIN | 5.1% | 6.9% | 28.9% |
TORRENT PHARMACEUTICALS | 1.5% | 7.8% | 15.5% |
Ratio | Value |
---|---|
P/E P/B P/S |
26.79
P/E Calculated based on EPS of 16.31
[ Mar2020 - Standalone Results ] 5.38
P/B Calculated based on Book Value of 81.18
[ Mar2020 - Standalone Results ] 1.32
P/S Calculated based on Revenues of 458.148 Cr
[ TTM - Standalone Results ] |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
NA 59% 67% |
Pledged Shares |
0 % |
---|---|
As on : Sep2020 | |
If less than 25% | Good |
If between 25% and 50% | Neutral |
If greater than 50% | Bad |